long intergenic non-protein coding RNA 1691Genealiases: []
Q-omics provides the consensus-scored LINC01691 profile across patient tissues and cancer cell-line models. LINC01691 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, LINC01691 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, LINC01691 RNA expression shows 11,168 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, HNSC, and THYM as cancer lineages where LINC01691 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01691 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01691 survival associations across molecular data types. LINC01691 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01691 RNA expression–survival associations across cancer types. High LINC01691 expression shows unfavorable associations in LIHC, KIRC, KIRP and READ, but favorable associations in BRCA and SKCM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for LINC01691 RNA expression.
This table summarizes LINC01691 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01691. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01691 shows higher tumor expression in HNSC, STAD, LUAD, LUSC, UCEC and BRCA. The HNSC box plot shows higher LINC01691 RNA expression in tumor versus normal tissue (log2 FC = +0.184, t-test p < 0.001).
This table shows molecular features associated with LINC01691 in patient tissues and cancer cell lines. In patient samples, LINC01691 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
